secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2026-06-15T20:05:50+00:00
Accession:  0001193125-26-271071
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma shareholders elect three directors, ratify EY, approve say-on-pay at 2026 annual meeting
--------------------------------------------------------------------------------

- Quorum of 67.31% (15,706,826 shares) present; all three proposals passed.
- Elected Class II directors Richard Klausner, Otis Brawley, William Rieflin with >99.2% of votes cast in favor each.
- Ratified Ernst & Young as independent auditor for FY2026: 15,674,347 for, 30,758 against, 1,721 abstain.
- Advisory vote on named executive officer compensation passed: 11,860,218 for, 6,613 against, 410,709 abstain, 3,429,286 broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/0001193125-26-271071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/d102015d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-271071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer